Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | LAP3 | P28838 | 4/20 | 0.45 |
| ▸ | ANPEP | P15144 | 2/20 | 0.45 |
| ▸ | ACP3 | P15309 | 1/20 | 0.44 |
| ▸ | ALPI | P09923 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.43 |
| ▸ | XIAP | P98170 | 1/20 | 0.43 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.43 |
| ▸ | ERAP2 | Q6P179 | 2/20 | 0.41 |
| ▸ | CPA1 | P15085 | 2/20 | 0.41 |
| ▸ | CPA3 | P15088 | 2/20 | 0.41 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.41 |
| ▸ | CPB1 | P15086 | 1/20 | 0.41 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | SRR | Q9GZT4 | 1/20 | 0.40 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.40 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.40 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9715671 | 1.00 | CYP1A2 (0.46) | CYP1A2LAP3ANPEPACP3ALPI | |
| SCHEMBL9715668 | 0.86 | LAP3 (0.47) | CYP1A2LAP3ANPEPACP3ALPI | |
| SCHEMBL9715672 | 0.86 | CYP1A2 (0.44) | CYP1A2LAP3ANPEPACP3ALPI | |
| SCHEMBL9715664 | 0.86 | CYP1A2 (0.44) | CYP1A2LAP3ANPEPACP3ALPI | |
| SCHEMBL962281 | 0.86 | LAP3 (0.47) | CYP1A2LAP3ANPEPACP3ALPI | |
| SCHEMBL9715674 | 0.86 | CYP1A2 (0.44) | CYP1A2LAP3ANPEPACP3ALPI | |
| SCHEMBL9715663 | 0.86 | CYP1A2 (0.44) | CYP1A2LAP3ANPEPACP3ALPI | |
| SCHEMBL14637889 | 0.81 | CYP1A2 (0.50) | CYP1A2LAP3ANPEPACP3ALPI | |
| SCHEMBL14637890 | 0.81 | CYP1A2 (0.50) | CYP1A2LAP3ANPEPACP3ALPI | |
| SCHEMBL1486794 | 0.81 | ANPEP (0.48) | CYP1A2LAP3ANPEPSLC7A5ERAP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070042966-A1 | Inhibition of cell motility, angiogenesis, and metastasis | Gov't of the USA, represented by the Secretary, Dep't of Health and Human Services (US) | 2007-02-22 | — | — | US | claimed |
| US-7132392-B1 | Inhibition of cell motility and angiogenesis by inhibitors of Grb2-SH2-domain | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2006-11-07 | — | — | US | claimed |
| EP-1223959-A2 | INHBITION OF CELL MOTILITY AND ANGIOGENESIS BY INHIBITORS OF THE GRB2 SH2-DOMAIN | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2002-07-24 | — | — | EP | claimed |
| US-6307090-B1 | OXALYL ENDCAPPED; CONTAINING A BIVALENT RADICAL OF PHOSPHOTYROSINE OR A PHOSPHOTYROSINE MIMETIC | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2001-10-23 | — | — | US | claimed |
| WO-2001028577-A2 | INHIBITION OF CELL MOTILITY AND ANGIOGENESIS BY INHIBITORS OF THE GRB2 SH2-DOMAIN | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2001-04-26 | — | — | WO | claimed |
| EP-0846127-A1 | ACYLATED OLIGOPEPTIDE DERIVATIVES HAVING CELL SIGNAL INHIBITING ACTIVITY | Novartis AG (CH) | 1998-06-10 | — | — | EP | claimed |
| WO-1997008193-A1 | ACYLATED OLIGOPEPTIDE DERIVATIVES HAVING CELL SIGNAL INHIBITING ACTIVITY | NOVARTIS AG (CH) | 1997-03-06 | — | — | WO | claimed |
| WO-1994007913-A1 | PEPTIDE ANTAGONISTS OF SH2 BINDING AND THERAPEUTIC USES THEREOF | WARNER-LAMBERT COMPANY (US) | 1994-04-14 | — | — | WO | claimed |
| US-7871981-B2 | Inhibition of cell motility, angiogenesis, and metastasis | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2011-01-18 | — | — | US | disclosed |
| WO-2008036565-A1 | TRIPEPTIDES FOR TREATING CANCER METASTASIS, PROSTATE CANCER AND MELANOMA | GOVERNMENT OF THE UNITED STATES, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2008-03-27 | — | — | WO | disclosed |
| EP-1223959-B1 | INHIBITION OF CELL MOTILITY AND ANGIOGENESIS BY INHIBITORS OF THE GRB2 SH2-DOMAIN | US GOV HEALTH & HUMAN SERV (US) | 2007-05-23 | — | — | EP | disclosed |
| US-20070042966-A1 | Inhibition of cell motility, angiogenesis, and metastasis | Gov't of the USA, represented by the Secretary, Dep't of Health and Human Services (US) | 2007-02-22 | — | — | US | disclosed |
| US-7132392-B1 | Inhibition of cell motility and angiogenesis by inhibitors of Grb2-SH2-domain | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2006-11-07 | — | — | US | disclosed |
| EP-1223959-A2 | INHBITION OF CELL MOTILITY AND ANGIOGENESIS BY INHIBITORS OF THE GRB2 SH2-DOMAIN | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2002-07-24 | — | — | EP | disclosed |
| US-6307090-B1 | OXALYL ENDCAPPED; CONTAINING A BIVALENT RADICAL OF PHOSPHOTYROSINE OR A PHOSPHOTYROSINE MIMETIC | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2001-10-23 | — | — | US | disclosed |
| WO-2001028577-A2 | INHIBITION OF CELL MOTILITY AND ANGIOGENESIS BY INHIBITORS OF THE GRB2 SH2-DOMAIN | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2001-04-26 | — | — | WO | disclosed |
| EP-0846127-A1 | ACYLATED OLIGOPEPTIDE DERIVATIVES HAVING CELL SIGNAL INHIBITING ACTIVITY | Novartis AG (CH) | 1998-06-10 | — | — | EP | disclosed |
| WO-1997008193-A1 | ACYLATED OLIGOPEPTIDE DERIVATIVES HAVING CELL SIGNAL INHIBITING ACTIVITY | NOVARTIS AG (CH) | 1997-03-06 | — | — | WO | disclosed |
| WO-1997007131-A1 | ACYLATED OLIGOPEPTIDES CONTAINING PHOSPHOTYROSINE AS INHIBITORS OF PROTEIN TYROSINE KINASES | NOVARTIS AG (CH) | 1997-02-27 | — | — | WO | disclosed |
| WO-1994007913-A1 | PEPTIDE ANTAGONISTS OF SH2 BINDING AND THERAPEUTIC USES THEREOF | WARNER-LAMBERT COMPANY (US) | 1994-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070042966-A1 | Inhibition of cell motility, angiogenesis, and metastasis | HGF, HDGF, MET | CYP1A2 4880/4885LAP3 478/4885ANPEP 366/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.